NASDAQ · LSTA
Healthcare · Biotechnology
$1.21
Down-$0.05 (-3.97%)
Updated Oct 7, 2026, 10:38 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LSTA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
LSTA closed at $1.21 after 21 trading sessions, down 34.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.31 | $1.3199 | $1.14 | $1.21 | 124.18K |
| Oct 5, 2026 | $1.45 | $1.475 | $1.26 | $1.26 | 90.75K |
| Oct 2, 2026 | $1.49 | $1.50 | $1.47 | $1.47 | 3.68K |
| Oct 1, 2026 | $1.42 | $1.56 | $1.42 | $1.49 | 63.14K |
| Sep 30, 2026 | $1.47 | $1.50 | $1.435 | $1.44 | 17.08K |
| Sep 29, 2026 | $1.48 | $1.5359 | $1.44 | $1.47 | 50.72K |
| Sep 28, 2026 | $1.56 | $1.57 | $1.50 | $1.50 | 38.18K |
| Sep 25, 2026 | $1.54 | $1.58 | $1.49 | $1.58 | 47.9K |
| Sep 24, 2026 | $1.47 | $1.53 | $1.435 | $1.50 | 25.48K |
| Sep 23, 2026 | $1.46 | $1.50 | $1.40 | $1.435 | 77.24K |
| Sep 22, 2026 | $1.55 | $1.60 | $1.44 | $1.48 | 152.76K |
| Sep 21, 2026 | $1.64 | $1.65 | $1.54 | $1.56 | 228.89K |
| Sep 18, 2026 | $1.71 | $1.76 | $1.61 | $1.70 | 293.91K |
| Sep 17, 2026 | $2.50 | $2.56 | $1.50 | $1.74 | 3.04M |
| Sep 16, 2026 | $1.53 | $1.57 | $1.47 | $1.47 | 93.54K |
| Sep 15, 2026 | $1.53 | $1.56 | $1.43 | $1.54 | 157.87K |
| Sep 14, 2026 | $1.68 | $1.68 | $1.455 | $1.56 | 169.19K |
| Sep 11, 2026 | $1.72 | $1.72 | $1.5673 | $1.63 | 111.89K |
| Sep 10, 2026 | $1.915 | $1.915 | $1.5381 | $1.64 | 236.64K |
| Sep 9, 2026 | $1.86 | $1.999 | $1.73 | $1.90 | 208.27K |
| Sep 8, 2026 | $1.65 | $1.89 | $1.62 | $1.86 | 252.5K |
The latest Smart Investors Daily articles mentioning LSTA.
Company
Market Activity
Research & News
LSTA research
Company profile and research snapshot.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 21, 2026 | Brookline Capital | Hold | — |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2025 | Brookline Capital | Buy | — |
| Dec 11, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 24, 2026
Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an...
Yahoo · Sep 24, 2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic functionSOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-g
Yahoo · Sep 24, 2026
Dow Jones futures: 51,672.00 points, down 201 points. S&P 500 futures: 7,723.25 points, down 49.25 points. Nasdaq 100 futures: 30,437.75 points, down 327 points. FTSE 100: 10,722.01 points, up 16.75 points. 8:15 EST: Wall Street preview Dow Jones futures is down 201 points at...
Yahoo · Sep 23, 2026
Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced on September 17 that it completed its acquisition of Marea Therapeutics and signed a definitive agreement for a concurrent private placement expected to raise approximately $225 million gross. Financing completion was expected on September 18, subject to customary closing conditions. Following both transactions, legacy equity holders of Lisata Therapeutics, Inc. […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LSTA.
